Invion Ltd (IVX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Invion Ltd (IVX) has a cash flow conversion efficiency ratio of -0.163x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-1.34 Million ≈ $-951.19K USD) by net assets (AU$8.25 Million ≈ $5.84 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Invion Ltd - Cash Flow Conversion Efficiency Trend (2006–2025)
This chart illustrates how Invion Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Invion Ltd debt and liabilities for a breakdown of total debt and financial obligations.
Invion Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Invion Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
C29 Metals Ltd
AU:C29
|
-0.213x |
|
Vanquis Banking Group PLC
LSE:VANQ
|
-0.241x |
|
ATI Physical Therapy Inc
NYSE:ATIP
|
-0.071x |
|
Genetic Technologies Ltd
NASDAQ:GENE
|
-3.096x |
|
Imagine Lithium Inc
V:ILI
|
-0.005x |
|
WOODPECKER.CO ZY -10
F:8FG
|
N/A |
|
PDZ Holdings Bhd
KLSE:6254
|
0.108x |
|
Aptose Biosciences Inc
TO:APS
|
0.381x |
Annual Cash Flow Conversion Efficiency for Invion Ltd (2006–2025)
The table below shows the annual cash flow conversion efficiency of Invion Ltd from 2006 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Invion Ltd worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | AU$8.25 Million ≈ $5.84 Million |
AU$-2.97 Million ≈ $-2.10 Million |
-0.360x | -116.34% |
| 2024-06-30 | AU$14.44 Million ≈ $10.22 Million |
AU$-2.40 Million ≈ $-1.70 Million |
-0.166x | -68.80% |
| 2023-06-30 | AU$18.40 Million ≈ $13.02 Million |
AU$-1.81 Million ≈ $-1.28 Million |
-0.099x | -73.98% |
| 2022-06-30 | AU$19.58 Million ≈ $13.85 Million |
AU$-1.11 Million ≈ $-784.62K |
-0.057x | -164.92% |
| 2021-06-30 | AU$4.79 Million ≈ $3.39 Million |
AU$417.98K ≈ $295.74K |
0.087x | +410.95% |
| 2020-06-30 | AU$5.43 Million ≈ $3.84 Million |
AU$-152.47K ≈ $-107.88K |
-0.028x | +92.73% |
| 2019-06-30 | AU$5.46 Million ≈ $3.86 Million |
AU$-2.11 Million ≈ $-1.49 Million |
-0.386x | -531.44% |
| 2018-06-30 | AU$7.91 Million ≈ $5.59 Million |
AU$707.09K ≈ $500.31K |
0.089x | +245.01% |
| 2017-06-30 | AU$4.01 Million ≈ $2.84 Million |
AU$-247.14K ≈ $-174.87K |
-0.062x | +90.36% |
| 2016-06-30 | AU$5.99 Million ≈ $4.24 Million |
AU$-3.83 Million ≈ $-2.71 Million |
-0.640x | +56.67% |
| 2015-06-30 | AU$6.86 Million ≈ $4.85 Million |
AU$-10.13 Million ≈ $-7.17 Million |
-1.477x | -244.59% |
| 2014-06-30 | AU$10.16 Million ≈ $7.19 Million |
AU$-4.35 Million ≈ $-3.08 Million |
-0.429x | -36.75% |
| 2013-06-30 | AU$11.04 Million ≈ $7.81 Million |
AU$-3.46 Million ≈ $-2.45 Million |
-0.313x | +82.26% |
| 2012-06-30 | AU$6.01 Million ≈ $4.25 Million |
AU$-10.62 Million ≈ $-7.51 Million |
-1.766x | -128.12% |
| 2011-06-30 | AU$-2.14 Million ≈ $-1.52 Million |
AU$-13.46 Million ≈ $-9.52 Million |
6.281x | +97.36% |
| 2010-06-30 | AU$-4.78 Million ≈ $-3.38 Million |
AU$-15.20 Million ≈ $-10.76 Million |
3.182x | +4.10% |
| 2008-06-30 | AU$-3.23 Million ≈ $-2.28 Million |
AU$-9.86 Million ≈ $-6.98 Million |
3.057x | +117.84% |
| 2007-06-30 | AU$715.28K ≈ $506.11K |
AU$-12.26 Million ≈ $-8.67 Million |
-17.134x | -597.95% |
| 2006-06-30 | AU$4.83 Million ≈ $3.42 Million |
AU$-11.87 Million ≈ $-8.40 Million |
-2.455x | -- |
About Invion Ltd
Invion Limited, a clinical-stage life sciences company, researches and develops Photosoft technology for the treatment of cancers, atherosclerosis, and infectious diseases in Australia. The company develops IVX-PDT, a photosensitising agent to treat a range of cancers, such as skin, prostate, ano-genital, glioblastoma multiforme, lung, and ovarian cancers; and human papilloma virus. It is also in… Read more